257 related articles for article (PubMed ID: 16091059)
1. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
[TBL] [Abstract][Full Text] [Related]
2. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
3. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
4. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
6. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
Hsu WC; Chan SC; Ting LL; Chung NN; Wang PM; Ying KS; Shin JS; Chao CJ; Lin GD
Jpn J Clin Oncol; 2006 Feb; 36(2):93-9. PubMed ID: 16517834
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
8. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation.
Tsai MC; Wang JH; Hung CH; Kee KM; Yen YH; Lee CM; Hu TH; Chen CH; Lu SN
J Gastroenterol Hepatol; 2010 Mar; 25(3):605-12. PubMed ID: 20074164
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma.
Mitsuhashi N; Kobayashi S; Doki T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Yoshitomi H; Nozawa S; Furukawa K; Takeuchi D; Suda K; Miura S; Miyazaki M
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e189-97. PubMed ID: 18466288
[TBL] [Abstract][Full Text] [Related]
10. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center.
Huo TI; Huang YH; Lui WY; Wu JC; Lee PC; Chang FY; Lee SD
Oncol Rep; 2004 Feb; 11(2):543-50. PubMed ID: 14719097
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
12. Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation.
Kubo S; Kinoshita H; Hirohashi K; Tanaka H; Tsukamoto T; Hamba H; Shuto T; Yamamoto T; Ikebe T; Wakasa K
Hepatogastroenterology; 1999; 46(30):3212-5. PubMed ID: 10626188
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
14. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy.
Kao WY; Chiou YY; Hung HH; Su CW; Chou YH; Wu JC; Huo TI; Huang YH; Wu WC; Lin HC; Lee SD
Clin Radiol; 2012 May; 67(5):429-36. PubMed ID: 22153231
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
17. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
18. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
Giannini EG; Marenco S; Borgonovo G; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Anna Di Nolfo M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
Hepatology; 2012 Oct; 56(4):1371-9. PubMed ID: 22535689
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
[TBL] [Abstract][Full Text] [Related]
20. Comparison of staging systems to predict survival in hepatocellular carcinoma.
Pascual S; Zapater P; Such J; García-Herola A; Sempere L; Irurzun J; Palazón JM; Carnicer F; Pérez-Mateo M
Liver Int; 2006 Aug; 26(6):673-9. PubMed ID: 16842323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
